Filter Results:
(34)
Show Results For
- All HBS Web
(161)
- Faculty Publications (34)
Show Results For
- All HBS Web
(161)
- Faculty Publications (34)
Novartis →
Page 1 of 34
Results →
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Leadership; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Testing and Trials; Health Care and Treatment; Business Model; Problems and Challenges; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- 24 Feb 2022
- Other Presentation
The Fearless ICU
By: Amy C. Edmondson
The last 24 months have pushed ICU teams around the world to their limits. As we move forward, we need to heal and rebuild our critical care teams. Healthcare more than ever will require ICU teams to perform at the highest levels and to continuously innovate to deliver... View Details
Keywords: Psychological Safety; Teams; Critical Care; Health Care and Treatment; Groups and Teams; Performance Effectiveness
"The Fearless ICU." Critical Matters (podcast), Sound Physicians, February 24, 2022.
- 4 Oct 2021
- Other Presentation
Amy Edmondson, Professor Leadership & Management at Harvard
By: Amy C. Edmondson and Guy Bloom
Amy C. Edmondson is an American scholar of leadership, teaming, and organizational learning. She is currently the Novartis Professor of Leadership at Harvard Business School.
Amy is the author of seven books and more than 75 articles and case studies.
She is... View Details
She is... View Details
"Amy Edmondson, Professor Leadership & Management at Harvard." Leadership Bites (podcast), October 4, 2021.
- 2 Sep 2021
- Interview
Amy Edmondson
By: Amy C. Edmondson and Deepak Jayaraman
Amy C. Edmondson is the Novartis Professor of Leadership and Management at the Harvard Business School.
Amy has been recognized by the biannual Thinkers50 global ranking of management thinkers since 2011, and most recently was ranked #3 in 2019. She studies teaming,... View Details
"Amy Edmondson." Episode 78. Play to Potential (podcast), September 2, 2021.
- 15 Jul 2021
- Interview
The Secret to Building a Higher-Performing Company—Amy Edmondson
By: Amy C. Edmondson and Jason Marc Campbell
Research shows that organizations with higher levels of psychological safety perform better on almost any metric or KPI than organizations with a low psychological safety score. Psychological safety is "a belief that one will not be punished or humiliated for speaking... View Details
"The Secret to Building a Higher-Performing Company—Amy Edmondson." Selling with Love (podcast), July 15, 2021. (Formerly Superhumans at Work.)
- 12 Jul 2021
- Interview
LeadershipLIVE™—Dr. Amy Edmondson
By: Amy C. Edmondson and Tom Matthews
Dr. Amy Edmondson has made a career studying leadership in influential businesses, becoming a world-class leader in the process. A protege of the late Larry Wilson, she’s built a rock-solid foundation on his wisdom. Dr. Edmondson is now the Novartis Professor of... View Details
"LeadershipLIVE™—Dr. Amy Edmondson." LeadershipNOW (podcast), July 12, 2021.
- 28 Dec 2020
- Interview
Psychological Safety and Fearless Organisations
By: Amy C. Edmondson and Vesna Lucca
In This Podcast:
• The ugly and beauty in transformational change
• Why don’t all companies create psychological safety
• Her passion to create a better workplace
• Buckminster Fuller
• The importance of system thinking
• The power... View Details
• The ugly and beauty in transformational change
• Why don’t all companies create psychological safety
• Her passion to create a better workplace
• Buckminster Fuller
• The importance of system thinking
• The power... View Details
"Psychological Safety and Fearless Organisations." Episode 112. Corporate Unplugged (podcast), December 28, 2020.
- November 2019
- Case
The Genesis Lab at Novartis
By: Amy C. Edmondson, Ranjay Gulati, Patrick J. Healy and Kerry Herman
Novartis' Genesis Labs program, launched in 2016 as part of Novartis Institutes for Biomedical Research (NIBR), hosted pitch competitions where teams of NIBR scientists proposed ideas to explore that aimed to revolutionize drug discovery. The goal was to break down... View Details
Keywords: Drug Discovery; Health Care and Treatment; Research and Development; Innovation and Invention; Programs; Management
Edmondson, Amy C., Ranjay Gulati, Patrick J. Healy, and Kerry Herman. "The Genesis Lab at Novartis." Harvard Business School Case 620-007, November 2019.
- 14 Apr 2019
- Interview
How to Build Psychological Safety, with Amy Edmondson
By: Amy C. Edmondson and Dave Stachowiak
Amy Edmondson is the Novartis Professor of Leadership and Management at the Harvard Business School. She has been recognized by the Thinkers50 global ranking of management thinkers for many years and was honored with their Talent Award in 2017. Amy is the author of... View Details
"How to Build Psychological Safety, with Amy Edmondson." Episode 404. Coaching for Leaders (podcast), April 14, 2019.
- January 2017 (Revised October 2018)
- Case
Novartis: A Transformative Deal
By: David Collis and Ashley Hartman
When Joe Jimenez became CEO of Swiss-based Novartis in 2010, replacing longtime CEO Dan Vasella, he assumed control of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and... View Details
Keywords: Novartis; GlaxoSmithKline; Asset Swap; Acquisitions; Divestiture; Strategy Alignment; Pharmaceuticals; Strategy; Business Strategy; Corporate Strategy; Diversification; Consolidation; Mergers and Acquisitions; Pharmaceutical Industry
Collis, David, and Ashley Hartman. "Novartis: A Transformative Deal." Harvard Business School Case 717-453, January 2017. (Revised October 2018.)
- April 2015
- Supplement
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (B)
By: Gautam Mukunda, Thomas DeLong and Aldo Sesia
This (B) case describes the actions André Wyss, president of Novartis Pharmaceuticals Corporation, took in early 2012 to transform the company's General Medicines group and build its specialty medications, marketing the selling capabilities in the face of falling... View Details
Keywords: LEAD; Leadership And Change Management; Talent Management; Organizational Change and Adaptation; Leadership; Change Management; Talent and Talent Management; Pharmaceutical Industry; United States
Mukunda, Gautam, Thomas DeLong, and Aldo Sesia. "Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (B)." Harvard Business School Supplement 415-049, April 2015.
- March 2015
- Case
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (A)
By: Gautam Mukunda, Thomas DeLong and Aldo Sesia
Over the course of a tumultuous weekend in April 2010, André Wyss was put in charge of Novartis Pharmaceuticals Corporation (NPC), the U.S. sales and marketing subsidiary of Novartis Pharma AG. He was brought in at a critical point in the organization's evolution with... View Details
Keywords: LEAD; Talent Management; Leadership And Change Management; Change Management; Organizational Change and Adaptation; Restructuring; Pharmaceutical Industry; United States
Mukunda, Gautam, Thomas DeLong, and Aldo Sesia. "Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (A)." Harvard Business School Case 415-013, March 2015.
- December 2014 (Revised October 2017)
- Case
Social Business at Novartis: Arogya Parivar
By: Michael E. Porter, Mark R. Kramer and David Lane
Late in 2013, Novartis CEO Joseph Jimenez was considering whether or how to deepen the company's investment in Arogya Parivar, its profitable program that sold Novartis medicines in rural India while expanding access to medicine and health information to millions of... View Details
Keywords: Shared Value; India; Kenya; Vietnam; Novartis; Arogya Parivar; Social Business; Multinational Firms and Management; Competitive Advantage; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Viet Nam; Kenya; India
Porter, Michael E., Mark R. Kramer, and David Lane. "Social Business at Novartis: Arogya Parivar." Harvard Business School Case 715-411, December 2014. (Revised October 2017.)
- March 2014
- Case
Novartis' Sandoz: Between Generics and Pharma
By: Krishna Palepu and Carin-Isabel Knoop
Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What... View Details
Keywords: Global Strategy And Leadership; Managing Within A Multi-Business Organization; Generic Pharmaceuticals; Global Strategy
Palepu, Krishna, and Carin-Isabel Knoop. "Novartis' Sandoz: Between Generics and Pharma." Harvard Business School Case 114-033, March 2014.
- May 2013 (Revised October 2014)
- Case
Novartis: Leading a Global Enterprise
By: William W. George, Krishna G. Palepu and Carin-Isabel Knoop
Novartis, the world's leading healthcare company, was formed in 1996 out of a merger of two very different, mid-tier Switzerland-based pharma companies. The case traces the company's evolution over the past 17 years, as it transformed into a truly global enterprise... View Details
Keywords: Multinational Firms and Management; Talent and Talent Management; Organizational Structure; Organizational Culture; Success; Globalized Markets and Industries; Management Teams; Change Management; Business History; Mergers and Acquisitions; Global Strategy; Health Care and Treatment; Pharmaceutical Industry; Health Industry; Switzerland
George, William W., Krishna G. Palepu, and Carin-Isabel Knoop. "Novartis: Leading a Global Enterprise." Harvard Business School Case 413-096, May 2013. (Revised October 2014.)
- June 2012
- Teaching Note
Cynthia Hogan and the Birth of Novartis (TN)
By: Rosabeth M. Kanter and Matthew Bird
- 2011
- Interview
Creating Shared Value: Connecting Business, Societal Value and Opportunity
By: Michael E. Porter, Mark R. Kramer and Jane Nelson
Michael Porter, Mark Kramer and Jane Nelson discuss creating shared value and give examples from HP, Nestlé and Novartis on how corporations can put this approach into practice. For more more information on creating shared value, visit www.fsg.org View Details
Keywords: Creating Shared Value; Value Creation; Corporate Social Responsibility and Impact; Business and Community Relations
Porter, Michael E., Mark R. Kramer, and Jane Nelson. "Creating Shared Value: Connecting Business, Societal Value and Opportunity." FSG, 2011.
- April 2009 (Revised April 2009)
- Case
Immusol and Novartis
By: Regina E. Herzlinger, Keyne M. Monson, Juan D. Betancourt and Victor Li
Should Immusol strive to become a fully integrated pharmaceutical company? How should a small pharmaceutical company structure a deal for its novel technology with the giant Novartis? View Details
Keywords: Technological Innovation; Rights; Negotiation Deal; Negotiation Participants; Alliances; Pharmaceutical Industry
Herzlinger, Regina E., Keyne M. Monson, and Juan D. Betancourt. "Immusol and Novartis." Harvard Business School Case 303-038, April 2009. (Revised from original October 2002 version.)